Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs

Veterinary Microbiology

Volumn 171, Issue 3-4, 2014, Pages 480-486

  Papich, Mark G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Antibiotic; Antimicrobial; Monte Carlo simulation; Pharmacodynamic; Pharmacokinetic; Resistance

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; VETERINARY DRUG;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL LABORATORY; CONCENTRATION RESPONSE; DRUG DOSE REGIMEN; DRUG USE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; STANDARD; ANIMAL; ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; BLOOD; DOSE CALCULATION; INAPPROPRIATE PRESCRIBING; MICROBIAL SENSITIVITY TEST; PREVENTION AND CONTROL; TIME; VETERINARY;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CEPHALOSPORINS; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MICROBIAL; INAPPROPRIATE PRESCRIBING; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; TIME FACTORS; VETERINARY DRUGS;

EID: 84901912110     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2013.12.021     Document Type: Article

References (34)

1. Ambrose P.G., Grasela D.M. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease 2000, 38:151-157.
2. Ambrose P.G. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2006, 26(1):129-134.
3. Andes, D., Craig, W.A., 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. International Journal of Antimicrobial Agents 19, 261-268.
4. Barger A., Fuhst C., Wiedemann B. Pharmacological indices in antibiotic therapy. Journal of Antimicrobial Chemotherapy 2003, 52:893-898.
5. Cars C. Pharmacokinetics of antibiotics in tissue and tissue fluids: a review. Scandinavian Journal of Infectious Diseases Supplement 1991, 74:23-33.
6. Cars C., Ogren S. Antibiotic tissue concentrations: methodological aspects and interpretation of results. Scandinavian Journal of Infectious Supplement 1985, 44:7-15.
7. CLSI, 2013. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved Standard-Fourth Edition. CLSI Document VET01-A4. Clinical and Laboratory Standards Institute, Wayne, PA (and Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Second Informational Supplement. CLSI document VET01-S2. Clinical and Laboratory Standards Institute, Wayne, PA).
8. Craig W.A. Pharmacokinetic/pharmacodynamic parmaters: rationale for antimicrobial dosing of mice and men. Clinical Infectious Diseases 1998, 26:1-12.
9. Drusano G.L., Johnson D.E., Rosen M., Standiford H.C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrobial Agents and Chemotherapy 1993, 37(March (3)):483-490.
10. Drusano G.L. Pharmacokinetics and pharmacodynamics of antimicrobials. Clinical Infect Disease 2007, 45(Suppl. 1):S89-S95.
11. Drusano G., Labro M.T., Cars O., Mendes P., Shah P., Sörgel F., Weber W. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clinical Microbiology and Infection 1998, 4(s2). 2S27-2S41.
12. Dudley M.N., Ambrose P.G., Bhavnani S.M., Craig W.A., Ferraro M.J., Jones R.N. For the Antimicrobial Susceptibility Testing Sub-Committee of the Clinical Laboratory Standards Institute. Background and rationale for revised Clinical Laboratory Standards Institute (CLSI) interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clinical Infectious Diseases 2013, 56(9):1301-1309.
13. Freeman C.D., Nicolau D.P., Belliveau P.P., Nightingale C.H. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. Journal of Antimicrobial Chemotherapy 1997, 39(677).
14. Frei C.R., Wiederhold N.P., Burgess D.S. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. Journal of Antimicrobial Chemotherapy 2008, 61:621-628.
15. Geor, R.J., Papich, M.G., 2003. Once-daily aminoglycoside dosing regimens. In: Robinson, N.E. (Ed.), Current Therapy in Equine Medicine, 5th ed. WB Saunders Co., Philadelphia, pp. 850-853.
16. Hawkey, P.M., 2008. The growing burden of antimicrobial resistance. Journal of Antimicrobial Chemotherapy 62 (Suppl. 1), i1-i9.
17. Hyatt J.M., McKinnon P.S., Zimmer G.S., Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clinical Pharmacokinetics 1995, 28:143-160.
18. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae-EUCAST and CLSI breakpoints. Clinical Microbiology and Infection 2008, 14(Suppl. 1):169-174.
19. Lees P., Aliabadi F.S. Rational dosing of antimicrobial drugs: animal versus humans. International Journal of Antimicrobial Agents 2002, 19:269-284.
20. Lees, P., Svendsen, O., Wiuff, C., 2008. Strategies to minimize the impact of antimicrobial treatment on the selection of resistant bacteria. In: Guardabassi, L., Jensen, L.B., Kruse, H. (Eds.), Guide to Antimicrobial Use in Animals. Blackwell Publishing, pp. 77-101 (Chapter 6).
21. Lode H., Borner K., Koeppe P. Pharmacodynamics of fluoroquinolones. Clinical Infectious Diseases 1998, 27:33-39.
22. Maaland M.G., Papich M.G., Turnidge J., Guardabassi L. Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline. Journal of Clinical Microbiology 2013, 51:3547-3554.
23. Maglio D., Nightingale C.H., Nicolau D.P. Extended interval aminoglycoside dosing: from concept to clinic. International Journal of Antimicrobial Agents 2002, 19:341-348.
24. McKellar Q.A., Sanchez Bruni S.F., Jones D.G. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:503-514.
25. Mouton J.W., Dudley M.N., Cars O., Derendorf H., Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. International Journal of Antimicrobial Agents 2002, 19:355-358.
26. Mouton J.W., Dudley M.N., Cars O., Derendorf H., Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. Journal of Antimicrobial Chemotherapy 2005, 55:601-607.
27. Nicolau D.P., Quintiliani R., Nightingale C.H. Antibiotic kinetics and dynamics for the clinician. Medical Clinics of North America 1995, 79:477-495.
28. Nix D.E., Goodwin S.D., Peloquin C.A. et al. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrobial Agents and Chemotherapy 1991, 35:1953-1959.
29. Papich M.G., Riviere J.E. Fluoroquinolone antimicrobial drugs. Veterinary Pharmacology and Therapeutics 2009, Wiley-Blackwell Publishing, Ames, Iowa, USA, 1524 pp. (Chapter 38). 9th ed. J.E. Riviere, M.G. Papich (Eds.).
30. Schwarz S., Silley P., Simjee S., Woodford N., Van Duijkeren E., Johnson A.P., Gaastra W. Assessing the antimicrobial susceptibility of bacteria obtained from animals. Veterinary Microbiology 2010, 141:1-4.
31. Soulsby L. The 2008 Garrod Lecture: antimicrobial resistance-animals and the environment. Journal of Antimicrobial Chemotherapy 2008, 62:229-233.
32. Tudor R.A., Papich M.G., Redding W.R. Gentamicin disposition and dosage determination of once daily administration of gentamicin sulfate in horses after abdominal surgery. Journal of the American Veterinary Medical Association 1999, 215(4):503-506.
33. Turnidge J.D. The pharmacodynamics of β-lactams. Clinical Infectious Diseases 1998, 27:10-22.
34. Wright, D.H., Brown, G.H., Peterson, M.L., Rotschafer, J.C., 2000. Application of fluoroquinolone pharmacodynamics. Journal of Antimicrobial Chemotherapy 46, 669-683.